RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TGA approves CBD down scheduling.From what I understand, LABS can ship to EU through Aussie subsidiairy. The bottleneck is product registration/ licensing approval. Once they obtain those licenses from german BfarM for their stada products, they'll be able to ship. Same for all the other intl markets (peru, brazil, denmark, UK, NZ).
Righttothetop wrote: LABS cannot be punished any further than it has given what the financials are. They can't ship Stada goods without EUGMP, which is wholly contingent on whether the German regulator comes across to validate....which, given the COVID circumstances, seems like a stretch and is completely outside the control of the business. Had COVID not happened, EUGMP would have been achieved months ago and we would be talking a different tune, but it didn't happen and likely won't happen until COVID simmers down.
The clock is indeed ticking, but there is more time left than that, and I would hope our BoD have a few timeouts to yet call.
Fladdi may have a point that a merger may be floated about, it was always likely going to happen regardless, but it was always eat or be eaten.....which will LABS be? It needs to recover a fair bit before anything M&A related makes any sense. Hopefully our Board agrees.
Lemoyne wrote: No doubt time is running out, but not merger wise, more like if they don't manage to make significant intl sales increase in Q1, they will be seriously punished.
Especially if they do not ship stada material in Q1.